<SEC-DOCUMENT>0000950170-24-096648.txt : 20240814
<SEC-HEADER>0000950170-24-096648.hdr.sgml : 20240814
<ACCEPTANCE-DATETIME>20240814071525
ACCESSION NUMBER:		0000950170-24-096648
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20240814
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240814
DATE AS OF CHANGE:		20240814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Viracta Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001061027
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				943295878
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51531
		FILM NUMBER:		241204139

	BUSINESS ADDRESS:	
		STREET 1:		2533 S COAST HWY 101
		STREET 2:		SUITE 210
		CITY:			CARDIFF
		STATE:			CA
		ZIP:			92007
		BUSINESS PHONE:		858-400-8470

	MAIL ADDRESS:	
		STREET 1:		2533 S COAST HWY 101
		STREET 2:		SUITE 210
		CITY:			CARDIFF
		STATE:			CA
		ZIP:			92007

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MOSAIC PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19980709

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUNESIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19980501
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>virx-20240814.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-08-14T03:01:52.6372+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:virx="http://viracta.com/20240814" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_ca979c45-5858-4a02-9874-884e318e77be" name="dei:AmendmentFlag" contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4">false</ix:nonNumeric><ix:nonNumeric id="F_0a028806-123e-4bdc-935b-ea0a148292b7" name="dei:EntityCentralIndexKey" contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4">0001061027</ix:nonNumeric><ix:nonNumeric id="F_c2885d22-9ee6-4caf-a7f2-5e14c607123d" name="dei:EntityRegistrantName" contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4">Viracta Therapeutics, Inc.</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="virx-20240814.xsd"/></ix:references><ix:resources><xbrli:context id="C_98aacdd6-9459-49cf-a10d-38541647a2a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001061027</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-14</xbrli:startDate><xbrli:endDate>2024-08-14</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="min-height:0.5in;"></div>
  <p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e125bc83-1c41-40c3-9ba6-526038384d6a" contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_1e692be0-a6da-4699-84af-db6d695e8e1c" contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">August 14, 2024</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c2885d22-9ee6-4caf-a7f2-5e14c607123d;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">VIRACTA THERAPEUTICS, INC.</span></span></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20%;"/>
    <td style="width:1%;"/>
    <td style="width:20%;"/>
    <td style="width:18%;"/>
    <td style="width:41%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6dcfec6a-185a-4f22-bbc4-36b422aaef4e" contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_9819ca33-e381-4ee9-98e8-1a75e1e11ba2" contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">000-51531</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_43878f90-ce9b-449f-91c6-72cfc62041c6" contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">94-3295878</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_bd5fb67e-7e64-4dae-ad62-21c308b1c814" contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2533 S. Coast Hwy. 101, Suite 210</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_09f4e20f-398a-4ca7-b018-9ae74e853f66" contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cardiff</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_a72a948b-bfb1-4f01-80e9-d7fb833560e9" contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_88a9ec8c-5c92-4187-be48-e27a9ce5d144" contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">92007</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_f19b5477-8a2c-42af-b77b-9a410f332c16" contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(858)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_05cd1bb2-892b-4704-b6c9-018863a6558d" contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">400-8470</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_59df26a0-2a43-4b30-8955-9a2a4ed9d042" contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d5e49025-4db3-4653-894d-8b06e2686966" contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de06bce0-0a9c-403e-b4ef-d75e8572872e" contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3ccde49d-f354-4d62-af87-65c8dcbbfa45" contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;"/>
    <td style="width:1%;"/>
    <td style="width:15%;"/>
    <td style="width:1%;"/>
    <td style="width:45%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Title of each class</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_11cb11e5-7f01-4f3f-b63f-4a265eb0aab5" contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock,  par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ab428b9d-902a-49ce-aa3d-583920380000" contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">VIRX</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_af1df8bf-ae65-4b89-ae7e-1493dbf9b63e" contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_80af43e0-4b9c-44b1-9585-a4b01fcc81ab" contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 14, 2024, Viracta Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of the information furnished in this Item 2.02 and the press release attached hereto as Exhibit 99.1 shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7.01. Regulation FD Disclosure.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Also on August 14, 2024, the Company issued a press release announcing certain business updates, including trial results, regulatory progress and plans, and an update to the clinical development plan. A copy of the press release is furnished herewith as Exhibit 99.2.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of the information furnished in this Item 7.01 and the press release attached hereto as Exhibit 99.2 shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(d) Exhibits</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:6.14%;"/>
    <td style="width:4.84%;"/>
    <td style="width:89.02%;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="virx-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press Release, dated August 14, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="virx-ex99_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press Release, dated August 14, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6%;"/>
    <td style="width:44%;"/>
    <td style="width:4%;"/>
    <td style="width:46%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Viracta Therapeutics, Inc</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 14, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Michael Faerm</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Michael Faerm<br/>Chief Financial Officer<br/>(Principal Financial and Accounting Officer)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>virx-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Reported combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial demonstrating Nana-val&#x2019;s substantial antitumor activity and generally well-tolerated safety profile -</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">New positive data and productive feedback from the FDA support updated Nana-val clinical development plan in EBV-positive PTCL patients; randomized controlled trial planned to begin in the second half of 2025 to support potential registration -</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Appointed Michael Faerm as Chief Financial Officer -</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">SAN DIEGO, August 14, 2024 &#x2013; Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today reported financial results for the second quarter of 2024 and provided a business update.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;In the second quarter, we took several important steps to drive forward our clinical development program for Nana-val, our first-in-class, all-oral combination treatment regimen for Epstein-Barr virus (EBV) associated cancers,&#x201d; said Mark Rothera, President and Chief Executive Officer of Viracta. &#x201c;We received productive feedback from our meeting with the FDA and are encouraged by additional positive data from the ongoing NAVAL-1 trial, particularly in the second-line EBV-positive PTCL subgroup. To optimize the clinical benefit of Nana-val, we plan to focus on the second-line EBV-positive PTCL subpopulation in the NAVAL-1 trial&#x2019;s expansion phase and initiate a randomized controlled trial in 2025 to potentially support registration. We believe our sharpened focus on the EBV-positive lymphoma program will propel us forward to key milestones and support our speed to market strategy. We look forward to providing more updates on our progress.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Clinical Trial Updates and Anticipated Milestones</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Phase 2 NAVAL-1 trial of Nana-val (nanatinostat in combination with valganciclovir) in patients with relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">) lymphoma</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Clinical Trial Updates</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Announced positive combined Stage 1 and Stage 2 data (n=21) in the R/R EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL cohort of patients treated with nanatinostat (20 mg orally once daily, 4 days/week) in combination with valganciclovir (900 mg orally once daily, 7 days/week) across the first two stages of the study. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">As of the June 28, 2024 data cutoff, combined Stages 1 and 2 data demonstrated Nana-val&#x2019;s substantial antitumor activity and generally well-tolerated safety profile with a</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">median duration of response (DOR) that has not yet been reached.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:16.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.999615998463994%;display:inline-flex;justify-content:flex-start;">&#x25aa;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In the R/R EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL population, the overall response rate (ORR) was 33% and the complete response rate (CRR) was 19% in the intent-to-treat (ITT) population (N=21); the ORR was 41% and the CRR was 24% in the efficacy-evaluable (EE) population (N=17).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:16.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.999615998463994%;display:inline-flex;justify-content:flex-start;">&#x25aa;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Notably, there was a particularly robust clinical response observed in the second-line EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL subpopulation, as the ORR was 60% and the CRR was 30% </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:16.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.999615998463994%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">in the intent-to-treat population (n=10), and the ORR was 67% and the CRR was 33% in the efficacy-evaluable population (n=9).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Held a productive FDA meeting to align on a potential regulatory path forward for Nana-val in patients with R/R EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL. Based on feedback from the FDA and the particularly robust response rates observed in the second-line treatment setting, Viracta will focus the primary analysis on the second-line EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL subpopulation in the ongoing NAVAL-1 trial&#x2019;s expansion phase. The Company plans to begin a randomized controlled trial (RCT) of Nana-val in the second-line treatment of EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL patients in 2025.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Viracta believes this strategy will best position Nana-val for a potential NDA filing in 2026 for accelerated approval based on an interim analysis of second-line EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL patient data from the NAVAL-1 trial, provided that the ORR and DOR are compelling and the RCT is well underway; for accelerated approval based on final analysis of NAVAL-1 trial data; or for accelerated or full approval based on the outcomes of the RCT at interim or final analysis, respectively. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Anticipated Milestones</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Viracta plans to deliver on the following milestones:</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The recommended Phase 2 dose in patients with advanced EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> solid tumors is expected to be determined in the second half of 2024.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Report additional data from the expansion phase of the NAVAL-1 trial in second-line EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL patients in the fourth quarter of 2024.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Report Stage 1 data from patients with R/R EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> diffuse large B-cell lymphoma (DLBCL) in the first half of 2025. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Meet with the FDA to finalize the proposed RCT design in the second-line treatment of patients with EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL in the first half of 2025.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Initiate the RCT in the second half of 2025.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Present interim analysis outcomes from the NAVAL-1 trial in second-line EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL patients in 2026.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">File NDA for accelerated approval in 2026 based on interim analysis of the NAVAL-1 trial&#x2019;s expansion cohort.</font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Business Updates</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Appointed Michael Faerm as Chief Financial Officer. Mr. Faerm is a seasoned biotech executive with more than 25 years of experience in life sciences companies, equity research and investment banking.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Viracta has aligned resources to prioritize its more advanced EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> lymphoma and will pause its EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> solid tumor program. Along with this pipeline reprioritization, a reduction in force has been implemented that impacts approximately 23% of the company&#x2019;s employees.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Second Quarter 2024 Financial Results</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Cash position</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> &#x2013; Cash, cash equivalents, and short-term investments totaled approximately $30.0 million as of June 30, 2024, which Viracta expects will be sufficient to fund operations late into the first quarter of 2025.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Research and development expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> &#x2013; Research and development expenses were approximately $6.5 million and $16.5 million for the three and six months ended June 30, 2024, respectively, compared to approximately $8.2 million and $15.8 million for the same periods in 2023. The decrease in research and development expenses for the three months ended June 30, </font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">2024 compared to the same period in 2023, was driven by decreases in costs incurred to support the advancement and expansion of our clinical development programs, including incremental costs to support NAVAL-1, our Phase 2 trial of Nana-val in patients with R/R EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> lymphomas and personnel-related costs. The increase in research and development expenses for the six months ended June 30, 2024 compared to the same period in 2023, was largely due to a non-cash adjustment for insurance costs related to the February 2021 reverse merger with Sunesis Pharmaceuticals of $1.8 million, partially offset by decrease in costs incurred related to our clinical development programs and personnel-related costs.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">General and administrative expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> &#x2013; General and administrative expenses were approximately $3.0 million and $7.0 million for the three and six months ended June 30, 2024, respectively, compared to $4.3 million and $8.9 million for the same periods in 2023. The decrease in general and administrative expenses was largely due to decreases in personnel-related costs, corporate liability insurance premiums and legal costs.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Net loss</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> &#x2013; Net loss was approximately $9.8 million, or $0.25 per share (basic and diluted), for the quarter ended June 30, 2024, compared to a net loss of $12.5 million, or $0.32 per share (basic and diluted), for the same period in 2023. This change was primarily the result of decreases in research and development expenses and personnel-related costs. Net loss was approximately $19.0 million, or $0.48 per share, (basic and diluted) for the six months ended June 30, 2024, compared to a net loss of $24.7 million, or $0.64 per share, (basic and diluted) for the same period in 2023. This change was primarily the result of $5.0 million of other income received related to the monetization of a pre-commercialization, event-based milestone from Day One Biopharmaceuticals, Inc. in March 2024, partially offset by the non-cash adjustment for insurance costs related to the February 2021 merger of $1.8 million.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About the NAVAL-1 Trial</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">NAVAL-1 (NCT05011058) is a global, multicenter, clinical trial of Nana-val in patients with relapsed or refractory (R/R) Epstein-Barr virus-positive</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">(EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">) lymphoma. This trial employs a Simon two-stage design where, in Stage 1, participants are enrolled into one of three indication cohorts based on EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> lymphoma subtype. If two objective responses are achieved within a lymphoma subtype in Stage 1 (n=10), then additional patients will be enrolled in Stage 2 for a total of 21 patients. EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> lymphoma subtypes demonstrating promising antitumor activity in Stage 2 may be further expanded following discussion with regulators to potentially support registration.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Nana-val (Nanatinostat and Valganciclovir)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Nanatinostat is an orally available histone deacetylase (HDAC) inhibitor being developed by Viracta. Nanatinostat is selective for specific isoforms of Class I HDACs, which are key to inducing viral genes that are epigenetically silenced in Epstein-Barr virus (EBV)-associated malignancies. Nanatinostat is currently being investigated in combination with the antiviral agent valganciclovir as an all-oral combination therapy, Nana-val, in various subtypes of EBV-associated malignancies. Ongoing trials include a potentially registrational, global, multicenter, open-label Phase 2 basket trial in multiple subtypes of relapsed or refractory (R/R) EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> lymphoma (NAVAL-1) as well as a multinational Phase 1b/2 clinical trial in patients with recurrent or metastatic (R/M) EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> NPC and other advanced EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> solid tumors.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Peripheral T-Cell Lymphoma</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">T-cell lymphomas comprise a heterogeneous group of rare and aggressive malignancies, including peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL). There are approximately 5,600 newly diagnosed T-cell lymphoma patients and approximately 2,600 newly diagnosed PTCL-NOS and AITL patients in the U.S. annually. Approximately</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">70% of these patients are either refractory to first-line therapy, or eventually experience relapse of their disease. Clinical trials are currently recommended for all lines of PTCL therapy, and most patients with R/R PTCL have poor outcomes, with median progression-free survival and median overall survival times reported to be 3.7 and 6.5 months, respectively. Approximately 40% to 65% of PTCL is associated with EBV, the incidence of EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL varies by geography, and reported outcomes for patients with EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL are inferior to those whose disease is EBV-negative. There is no approved targeted treatment specific for EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL, and therefore this represents a high unmet medical need.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About EBV-Associated Cancers</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Approximately 90% of the world's adult population is infected with EBV. Infections are commonly asymptomatic or associated with mononucleosis. Following infection, the virus remains latent in a small subset of cells for the duration of the patient's life. Cells containing latent virus are increasingly susceptible to malignant transformation. Patients who are immunocompromised are at an increased risk of developing EBV-positive (EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">) lymphomas. EBV is estimated to be associated with approximately 2% of the global cancer burden including lymphoma, nasopharyngeal carcinoma (NPC), and gastric cancer.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Viracta Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Viracta is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Viracta&#x2019;s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a potentially registrational, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">) lymphoma (NAVAL-1), as well as a multinational, open-label Phase 1b/2 clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> nasopharyngeal carcinoma (NPC) and other advanced EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> solid tumors. Viracta is also pursuing the application of its &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Kick and Kill</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; approach in other virus-related cancers.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#212529;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">For additional information, please visit </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">www.viracta.com</font></font><font style="color:#212529;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font><font style="color:#212529;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">This communication contains &#34;forward-looking&#34; statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the details, timeline and expected progress for Viracta's ongoing and anticipated clinical trials and updates regarding the same, Viracta&#x2019;s clinical focus and strategy, the Company&#x2019;s expectations related to the FDA submission process and timelines, expectations regarding the Company&#x2019;s target patient populations, and expectations regarding the Company&#x2019;s cash runway. Risks and uncertainties related to Viracta that may cause actual results to differ materially from those expressed or implied in any forward-looking statement include, but are not limited to: Viracta's ability to successfully enroll patients in and complete its ongoing and planned clinical trials; Viracta's plans to develop and commercialize its product candidates, including all oral combinations of nanatinostat and valganciclovir; the timing of initiation of Viracta's planned clinical trials; the timing of the availability of data from Viracta's clinical trials; previous preclinical and clinical results may not be predictive of future clinical results; the timing of any planned investigational new drug application or new drug application; Viracta's plans to research, develop, and commercialize its current and future product candidates; the clinical utility, potential benefits, and market acceptance of Viracta's product candidates; Viracta's ability to manufacture or supply nanatinostat, valganciclovir, and pembrolizumab for clinical testing; and Viracta's estimates regarding its</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ability to fund ongoing operations into 2025, future expenses, capital requirements, and need for additional financing in the future.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption &#34;Risk Factors&#34; and elsewhere in Viracta's reports and other documents that Viracta has filed, or will file, with the SEC from time to time and available at </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">www.sec.gov</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The forward-looking statements included in this communication are made only as of the date hereof. Viracta assumes no obligation and does not intend to update these forward-looking statements, except as required by law or applicable regulation.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Investor Relations Contact:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Michael Faerm</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Chief Financial Officer</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Viracta Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ir@viracta.com</font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></font><font style=""></font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">SOURCE Viracta Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">-- Financial tables attached &#x2013;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.109%;"></td>
    <td style="width:2.559%;"></td>
    <td style="width:1%;"></td>
    <td style="width:15.557%;"></td>
    <td style="width:1%;"></td>
    <td style="width:2.659%;"></td>
    <td style="width:2.559%;"></td>
    <td style="width:1%;"></td>
    <td style="width:15.557%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="9" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Viracta Therapeutics, Inc.</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="9" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Selected Balance Sheet Highlights</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="9" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">(in thousands)</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">(Unaudited)</font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and short-term investments</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,005</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,691</font></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,322</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56,692</font></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,651</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,373</font></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders' equity</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,671</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,319</font></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.184%;"></td>
    <td style="width:1.599%;"></td>
    <td style="width:1%;"></td>
    <td style="width:10.196%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.839%;"></td>
    <td style="width:1.599%;"></td>
    <td style="width:1%;"></td>
    <td style="width:10.196%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.839%;"></td>
    <td style="width:1.599%;"></td>
    <td style="width:1%;"></td>
    <td style="width:10.196%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.839%;"></td>
    <td style="width:1.719%;"></td>
    <td style="width:1%;"></td>
    <td style="width:10.196%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="19" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Viracta Therapeutics, Inc.</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="19" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Condensed Consolidated Statement of Operations and Comprehensive Loss</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="19" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">(in thousands except share and per share data)</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="19" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">(Unaudited)</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="7" style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended June 30,</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="7" style="vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</font></p></td>
    <td style="vertical-align:middle;border-bottom:2.25pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</font></p></td>
    <td style="vertical-align:middle;border-bottom:2.25pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</font></p></td>
    <td style="vertical-align:middle;border-bottom:2.25pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:middle;border-bottom:2.25pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</font></p></td>
    <td style="vertical-align:middle;border-bottom:2.25pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;$</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,548</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;$</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,197</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;$</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,504</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;$</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,804</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,041</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,253</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,961</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,853</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,589</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,450</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,465</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,657</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(9,589</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(12,450</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(23,465</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(24,657</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other income (expense)</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(241</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(34</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,494</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(36</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(9,830</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(12,484</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(18,971</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(24,693</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain (loss) on short-term investments</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(28</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(14</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(9,829</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(12,512</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(18,985</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(24,630</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;$</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(0.25</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;$</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(0.32</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;$</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(0.48</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;$</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(0.64</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average common shares <br>outstanding, basic and diluted</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,404,975</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,560,376</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,364,469</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,509,887</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>virx-ex99_2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<html>
 <head>
  <title>EX-99.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Exhibit 99.2</font></p></div>
  <p style="text-indent:3.39%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.667%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">New combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial further demonstrate Nana-val&#x2019;s substantial antitumor activity and generally well-tolerated safety profile -</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">- Productive FDA meeting held to align on a potential regulatory path forward for Nana-val in patients with relapsed or refractory EBV-positive PTCL -</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">- Updated Nana-val clinical development plan implemented to optimize its clinical benefit in EBV-positive PTCL patients and expedite a randomized controlled trial to support potential registration -</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">- Viracta to host conference call and webcast on Wednesday, August 14 at 8:30 a.m. ET, featuring Pierluigi Porcu, M.D., Professor of Medical Oncology, Director of the Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation at Thomas Jefferson University -</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">San Diego, August 14, 2024 &#x2013; Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today reported positive Phase 2 NAVAL-1 trial results from Stages 1 and 2 of the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">) peripheral T-cell lymphoma (PTCL) cohort. Additionally, the Company received productive feedback from its meeting with the U.S. Food and Drug Administration (FDA), providing clarity on the potential regulatory path to initial registration of Nana-val in patients with R/R EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL. Based on FDA&#x2019;s feedback, Viracta plans to begin a randomized controlled trial (RCT) of Nana-val in the second half of 2025.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;We are pleased to present important additional data from our NAVAL-1 trial, which further supports Nana-val&#x2019;s potential to address the high unmet medical needs of patients living with relapsed or refractory EBV-positive PTCL,&#x201d; said Darrel P. Cohen, M.D., Ph.D., Chief Medical Officer of Viracta. &#x201c;Nana-val demonstrated substantial antitumor activity with a generally well-tolerated safety profile across Stage 1 and Stage 2 of the relapsed or refractory EBV-positive PTCL cohort, with a median duration of response that has not yet been reached. We are also encouraged by the particularly robust clinical responses observed in the second-line EBV-positive PTCL subgroup.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Mark Rothera, President and Chief Executive Officer of Viracta, added, &#x201c;Aligning with the FDA on the potential path forward in relapsed or refractory EBV-positive PTCL marks a critical step towards bringing Nana-val to patients. EBV-positive PTCL is an aggressive cancer with survival rates that decline precipitously 12-24 months after diagnosis. Published literature suggests that EBV-positive lymphomas are a distinct oncological disease associated with poorer survival outcomes than EBV-negative lymphomas. We believe it is critical to treat these patients as early as possible with an EBV-targeted therapy to improve patient outcomes. Our updated Nana-val clinical development plan is designed to address this urgent need and expedite a randomized controlled trial, which we plan to initiate in 2025 to support potential registration.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Key Takeaways from the R/R EBV</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL Cohort of the Phase 2 NAVAL-1 Trial</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Overview: A total of 21 patients with primarily Stage III-IV disease (who had received &#x2265;1 [median 2] prior systemic PTCL therapies) received nanatinostat (20 mg orally once daily, 4 days/week) in combination</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Exhibit 99.2</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">with valganciclovir (900 mg orally once daily, 7 days/week) across the first two stages of the study. Data generated from the expansion phase of the R/R EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL cohort may be shared in future updates.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">As of the June 28, 2024 data cutoff, combined Stages 1 and 2 data demonstrated:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In the R/R EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL population:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The overall response rate (ORR) was 33% and the complete response rate (CRR) was 19% in the intent-to-treat (ITT) population (n=21); the ORR was 41% and the CRR was 24% in the efficacy-evaluable (EE) population (n=17).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In the second-line EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL subpopulation:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The ORR was 60% and the CRR was 30% in the ITT population (n=10); the ORR was 67% and the CRR was 33% in the EE population (n=9).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Median duration of response (DOR) has not yet been reached.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Two responding patients proceeded to hematopoietic stem-cell transplant without relapse, one of whom remains in response over 16 months. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Nana-val was generally well-tolerated:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The most common treatment-related adverse events were fatigue, nausea, decreased appetite, diarrhea, platelet count decreased, and anemia. These adverse events were primarily mild to moderate in severity and generally manageable or reversible. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Nana-val Clinical Development Plan: Next Steps</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Based on the Company&#x2019;s meeting with FDA and the particularly robust response rates observed in the second-line treatment setting, Viracta will focus Nana-val&#x2019;s clinical development on patients with R/R EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL as follows: First, the Company will focus the primary analysis on the second-line EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+ </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">PTCL subpopulation in the ongoing NAVAL-1 trial&#x2019;s expansion phase. Second, the Company plans to begin an RCT of Nana-val in the second-line treatment of EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL patients in 2025. Viracta believes this strategy will best position Nana-val for a potential NDA filing in 2026 for accelerated approval based on an interim analysis of second-line EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL patient data from the NAVAL-1 trial, provided that the ORR and DOR are compelling and the RCT is well underway. In addition, it creates the opportunity for accelerated approval based on final analysis of NAVAL-1 trial data, or for accelerated or full approval based on the outcomes of the RCT at interim or final analysis, respectively.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Corporate Update</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Viracta has aligned resources to prioritize its EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> lymphoma program and plans to deliver on key potential Nana-val development milestones as follows:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Pause the EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+ </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">solid tumor program to focus resources on the more advanced EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> lymphoma program.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The recommended Phase 2 dose in patients with advanced EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> solid tumors is expected to be determined in the second half of 2024. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Report additional data from the ongoing expansion phase of the NAVAL-1 trial in second-line EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL patients in the fourth quarter of 2024.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Report Stage 1 data from patients with R/R EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> diffuse large B-cell lymphoma (DLBCL) in the first half of 2025. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Meet with the FDA to finalize the proposed RCT design in the second-line treatment of patients with EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL in the first half of 2025.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Initiate the RCT in the second half of 2025.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Present interim analysis outcomes from the expansion phase of the NAVAL-1 trial in second-line EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL patients in 2026.</font></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Exhibit 99.2</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">File NDA for accelerated approval in 2026 based on interim analysis of the NAVAL-1 trial&#x2019;s expansion cohort.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Along with this pipeline reprioritization, a reduction in force has been implemented that impacts approximately 23% of the Company&#x2019;s employees.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Conference Call</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Viracta will host an investor call on Wednesday, August 14 at 8:30 a.m. ET to discuss the positive Phase 2 NAVAL-1 trial results from Stages 1 and 2 of the R/R EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL cohort. A live question and answer session will follow the formal presentation. To register, </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">click here</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About the NAVAL-1 Trial</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">NAVAL-1 (NCT05011058) is a global, multicenter, clinical trial of Nana-val in patients with relapsed or refractory (R/R) Epstein-Barr virus-positive</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">(EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">) lymphoma. This trial employs a Simon two-stage design where, in Stage 1, participants are enrolled into one of three indication cohorts based on EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> lymphoma subtype. If two objective responses are achieved within a lymphoma subtype in Stage 1 (n=10), then additional patients will be enrolled in Stage 2 for a total of 21 patients. EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> lymphoma subtypes demonstrating promising antitumor activity in Stage 2 may be further expanded following discussion with regulators to potentially support registration.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Nana-val (Nanatinostat and Valganciclovir)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Nanatinostat is an orally available histone deacetylase (HDAC) inhibitor being developed by Viracta. Nanatinostat is selective for specific isoforms of Class I HDACs, which are key to inducing viral genes that are epigenetically silenced in Epstein-Barr virus (EBV)-associated malignancies. Nanatinostat is currently being investigated in combination with the antiviral agent valganciclovir as an all-oral combination therapy, Nana-val, in various subtypes of EBV-associated malignancies. Ongoing trials include a potentially registrational, global, multicenter, open-label Phase 2 basket trial in multiple subtypes of relapsed or refractory (R/R) EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> lymphoma (NAVAL-1) as well as a multinational Phase 1b/2 clinical trial in patients with recurrent or metastatic (R/M) EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> NPC and other advanced EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> solid tumors.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Peripheral T-Cell Lymphoma</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">T-cell lymphomas comprise a heterogeneous group of rare and aggressive malignancies, including peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL). There are approximately 5,600 newly diagnosed T-cell lymphoma patients and approximately 2,600 newly diagnosed PTCL-NOS and AITL patients in the U.S. annually. Approximately 70% of these patients are either refractory to first-line therapy, or eventually experience relapse of their disease. Clinical trials are currently recommended for all lines of PTCL therapy, and most patients with R/R PTCL have poor outcomes, with median progression-free survival and median overall survival times reported to be 3.7 and 6.5 months, respectively. Approximately 40% to 65% of PTCL is associated with EBV, the incidence of EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL varies by geography, and reported outcomes for patients with EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL are inferior to those whose disease is EBV-negative. There is no approved targeted treatment specific for EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> PTCL, and therefore this represents a high unmet medical need.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About EBV-Associated Cancers</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Approximately 90% of the world's adult population is infected with EBV. Infections are commonly asymptomatic or associated with mononucleosis. Following infection, the virus remains latent in a small subset of cells for the duration of the patient's life. Cells containing latent virus are increasingly susceptible to malignant transformation. Patients who are immunocompromised are at an increased risk of</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Exhibit 99.2</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">developing EBV-positive (EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">) lymphomas. EBV is estimated to be associated with approximately 2% of the global cancer burden including lymphoma, nasopharyngeal carcinoma (NPC), and gastric cancer.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Viracta Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Viracta is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Viracta&#x2019;s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a potentially registrational, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">) lymphoma (NAVAL-1), as well as a multinational, open-label Phase 1b/2 clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> nasopharyngeal carcinoma (NPC) and other advanced EBV</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> solid tumors. Viracta is also pursuing the application of its &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Kick and Kill</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; approach in other virus-related cancers.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#212529;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">For additional information, please visit </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">www.viracta.com</font></font><font style="color:#212529;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font><font style="color:#212529;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">This communication contains &#34;forward-looking&#34; statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the details, timeline and expected progress for Viracta's ongoing and anticipated clinical trials and updates regarding the same, Viracta&#x2019;s clinical focus and strategy, the Company&#x2019;s expectations related to the FDA submission process and timelines, expectations regarding the Company&#x2019;s target patient populations, and expectations regarding the Company&#x2019;s cash runway. Risks and uncertainties related to Viracta that may cause actual results to differ materially from those expressed or implied in any forward-looking statement include, but are not limited to: Viracta's ability to successfully enroll patients in and complete its ongoing and planned clinical trials; Viracta's plans to develop and commercialize its product candidates, including all oral combinations of nanatinostat and valganciclovir; the timing of initiation of Viracta's planned clinical trials; the timing of the availability of data from Viracta's clinical trials; previous preclinical and clinical results may not be predictive of future clinical results; the timing of any planned investigational new drug application or new drug application; Viracta's plans to research, develop, and commercialize its current and future product candidates and the clinical utility, potential benefits, and market acceptance of Viracta's product candidates; Viracta's ability to manufacture or supply nanatinostat and valganciclovir for clinical testing.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption &#34;Risk Factors&#34; and elsewhere in Viracta's reports and other documents that Viracta has filed, or will file, with the SEC from time to time and available at </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">www.sec.gov</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The forward-looking statements included in this communication are made only as of the date hereof. Viracta assumes no obligation and does not intend to update these forward-looking statements, except as required by law or applicable regulation.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Investor Relations Contact:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Michael Faerm</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Exhibit 99.2</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Chief Financial Officer</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Viracta Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ir@viracta.com</font></font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">SOURCE Viracta Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>virx-20240814.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-08-14T03:01:53.1579+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://viracta.com/20240814" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:virx="http://viracta.com/20240814" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="virx-20240814.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140127568831200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 14, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 14,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Viracta Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001061027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-51531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3295878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2533 S. Coast Hwy. 101, Suite 210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cardiff<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">400-8470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock,  par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VIRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( .PY#ED'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #L.0Y9-/GOS>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)OI^FN(J&;B^))07!!\1:2V=U@DX9DI-VW-XV[740?P&-F_GSS
M#4RG@]!#Q.<X!(QD,5U-KO=)Z+!A!Z(@ )(^H%.IS@F?F[LA.D7Y&?<0E/Y0
M>X2V:6[ (2FC2,$,K,)"9+(S6NB(BH9XPAN]X,-G[ O,:, >'7I*P&L.3,X3
MPW'J.[@ 9AAA=.F[@&8AENJ?V-(!=DI.R2ZI<1SK<55R>0<.;T^/+V7=ROI$
MRFO,OY(5= RX8>?)KZN[^^T#DVW3KJOFMN+K+>>"7XN6O\^N/_PNPFXP=F?_
ML?%94';PZR[D%U!+ P04    " #L.0Y9F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M .PY#ED]%()R9@0  *T0   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI9AO<^(V$,:_BL;M=.YF$FP9$T@*S!"2]#)WEZ.!YCKM](6P9=#$MEQ)#N';
M=V6(35.S9J9O@O]H'_^T6C\K9[B1ZEFO.3?D-4TR/7+6QN17KJO#-4^9[LB<
M9W GEBIE!D[5RM6YXBPJ@]+$]3WOPDV9R)SQL+PV4^.A+$PB,CY31!=IRM3V
MFB=R,W*H\W;A4:S6QEYPQ\.<K?B<F]_RF8(SMU*)1,HS+61&%(]'SH1>7?N!
M#2A'/ F^T0?'Q$YE*>6S/;F/1HYGB7C"0V,E&/R\\"E/$JL$''_O19WJF3;P
M\/A-_:Z</$QFR32?RN2[B,QZY P<$O&8%8EYE)M/?#^AGM4+9:++OV2S&QL$
M#@D+;62Z#P:"5&2[7_:Z3\1A0/=(@+\/\$ONW8-*RAMFV'BHY(8H.QK4[$$Y
MU3(:X$1F5V5N%-P5$&?&-S(L(,F&3+*(W&9&F"VYSW:K#5D;N@8>8H>ZX5[P
M>B?H'Q&<%*L.H<$9\3T_^'>X"VP5H%\!^J5>]XC>5+YP1?Z<++51L(1_-1'M
M%()F!5O75SIG(1\Y4+B:JQ?NC'_Z@5YX/R-\W8JOBZG7"5QL<]X$AX</SC\C
M$$$%$: J$R"(2HJ[A*V:*/#XF"6:(QR]BJ-W6C)F7 EI"RHB4):-><&5JC)J
MJZ.+"NT"%=S7]B-?"5M)P/C TD8P7.=)V#)D9+'FBN6\,"+49_#*A!T$LE]!
M]D^!G$(*%4M ->*OY#/?-F'B2I[G4>^">GX?P1I46(-3L&Y3KE8B6Y%?(-ZL
MR52F.<L:X7"]MG*[K+@N3^&Z$PDG#T6ZY*J)!=> 1)WW:*]+$1[JU6[JG4($
MY2!5+E7IH6=D;N =(%)!Q@I865A@&3667HOZS2T&>6#Y]!3(!7LE]Q&4FHA%
M6)(B26R1O S.N_YE;] ?8(2UYU/4LM\()U$$A@VOU_Z ?(%QY%O6G#M<TN]U
MNV3>@=0S;<BGS1;LQ:.P-H6 M?&IAX'7S8#B=OX>?&K/8.$7<M/<2W&Y*5.1
MB&,,K6X1%/?X]VA54<Z4?!%9V)Q47',ZP=#JKD%QLW^/-I/:@/W](?+C;PJN
M> F[4LSY:-TV*.[WY0I.8,-[' 47^##H#3YB*'5SH+BG?Y$A9&6VEAEF=RTB
M ?C=(.BCY5[W!8H;^7<EC.&9[01ID>U=1#=2_;^.0.N60'$_G\M$A,+8-O45
M"EP)EC3RX"IM/'[=$7S<LV>*GX>0'@YOV&Z?"%LUV-%^B^/F]6O1:R6KVX"/
M>_9_R.ZU+H"L%1"7;04\V/GCEKT0!AJ[C GU/RP_DCD/"ZBWQOU&BY*M3VAO
M<R/#9]A2YDR1%Y84G/SH=>Q.B>0P8;UF"@6ONX"/V_9"L<@6X'R;+F5C^;4(
M/-T__HZ1U*;OXP;]EC-R^QJN6;;B1W>]+4(/D_G-Y-<F)O?@X]-^R']E=I.H
M2<)C4/(Z?7!JM?LVWIT8F9??HTMIX.NV/%QS!B5G!\#]6$KS=F(_<:O_4(S_
M 5!+ P04    " #L.0Y9GZ ;\+$"  #B#   #0   'AL+W-T>6QE<RYX;6S=
M5VUKVS 0_BM"/V!N8FKBD1BV0&&PC4+S85^56'8$>O%DN7/ZZZ>S;"=I=67=
MA['-H<G=/;J[1W<GF:Y;=Y+\X<BY([V2NMW0HW/-^R1I#T>N6/O.-%Q[I#)6
M,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?
MRA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K <XRBAC05C
M$C*$[_VX_!DP::U7A90SP24-AF+=,.>XU7=>&18/QA<0&>7=J?$,:\M.B^4M
M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#
ME_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\
M;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!
MI!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,
MD_'T7!S1JP,Z6PE<A!OZ%>Y7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?
M\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD<VWL,\E=,E[7FY'U=;[021>
M\%G'!QR>(W?#$T<PGX#%$<"P/!@#S"=X87G^I_VLT/T$#..VBB(KU&>%^@2O
M&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R
M^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%N
MV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ;  4/2='@/
M/GL?)=-[*CG_5U/\!%!+ P04    " #L.0Y9EXJ[',     3 @  "P   %]R
M96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:
MI7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$
MVV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_
M,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH
M^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( .PY#EDZJJ+G0 $  #P"
M   /    >&PO=V]R:V)O;VLN>&ULC5%=:\,P#/PKQC]@2<M66&D&8]U'86QE
M'7UW8J41M:U@J^W67S\E(:RPESW).HG3W7EQHK@OB?;JR[N0"MTPM_,L2U4#
MWJ0K:B'(I*;H#4L;=UEJ(QB;&@#V+IOF^2SS!H.^6XQ<ZYA=-L10,5(0L .V
M"*?T.^]:=<2$)3KD[T+W;P=:>0SH\0RVT+E6J:'3"T4\4V#C-E4DYPH]&09;
MB(S5'WC3B?PT9>H1-N6'$2&%GN5"6&-,W&_T_$8T'D&6A^[ ](2.(2X-PW.D
M0XMAU]&(B^S"1I_#6(<0Y_$_,5)=8P5+J@X> @\Y1G"=P) :;)-6P7@H]+BB
M[H-5CX$E)+4* Y7L=D[E],H.KEGD7F08YRB#N+*#\%&MA1H#V#<YD 27Y*IU
M5%WI>:;7-Y-;2>C@W(-@[^&5C!W-CQ]W]P-02P,$%     @ [#D.620>FZ*M
M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%
MKQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V
M\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\
M_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:
M(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( .PY#EEE
MD'F2&0$  ,\#   3    6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E
M6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#H
MG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4S
MM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*
MJX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ
M R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L
M^T%.6X.^D<WC_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!
M4$L! A0#%     @ [#D.60=!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #L.0Y9-/GOS>X    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" #L.0Y9F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( .PY#ED]%()R9@0  *T0   8
M      " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" #L.0Y9GZ ;\+$"  #B#   #0              @ &I#   >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( .PY#EF7BKL<P    !,"   +              "
M 84/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( .PY#EDZJJ+G0 $  #P"   /
M              "  6X0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #L
M.0Y9)!Z;HJT   #X 0  &@              @ ';$0  >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #L.0Y999!YDAD!  #/ P  $P
M            @ ' $@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 )
+ #X"   *%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="virx-20240814.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="virx-20240814.htm">virx-20240814.htm</File>
    <File>virx-20240814.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "virx-20240814.htm": {
   "nsprefix": "virx",
   "nsuri": "http://viracta.com/20240814",
   "dts": {
    "inline": {
     "local": [
      "virx-20240814.htm"
     ]
    },
    "schema": {
     "local": [
      "virx-20240814.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_98aacdd6-9459-49cf-a10d-38541647a2a4",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "virx-20240814.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_98aacdd6-9459-49cf-a10d-38541647a2a4",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "virx-20240814.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://viracta.com/20240814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-24-096648-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-096648-xbrl.zip
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M91:.U9?E!XD/@!9+X^7.I'22&CR$=E+"XG%5%H),36[P.XSA24Q#R%:US-:
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MNJ?&-366PL2W,GTCP?"''V+@$IDN= ':_R[&#)12Z%0!@M(@;#>HM5@8>@\
M\5V@4J'1/AA3MT)4O-*[#"+CLH/U+W(PIA[BJZ@O -)U*^>.LKS(()_I/'[6
M'%Q:';TBN?\]EPB4L@N0>E_&W-!<*X";GRXG$^LV;^:[&$OHS0Z #J*K40%9
M31$MRQLM[4_PU  IHQ\"Y"2'^,R$9^(#"WRC!U]??SV<LRM/L!.WYR=:A,!
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M]OC=W =&T_>7WKB7*1,+D[.)*5P"]!>>A>-ZZ)FJ7G@T]IJ'PEY3J(<J26N
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MYF2&7TIXQ;"YA*>N@RF(#?<*=QW?>1"H6Q&* B\4A0VA* >AB(%BD C\4Q!
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M#D8=&*.8G?-L 4)#4))4D!$P%QJP@Z@_0BR\=X'$UP+WA=2EZ7/ C$ 2^P@
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M_034Q[ZPX2^T#\#EG]KA\WUDSAC)O;/SI"UGM Y\K4 !Q$H7^W2T?9S/3*9
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M(DU^^W]02P$"% ,4    " #L.0Y9>@#CN*\3   (J0  $0
M@ $     =FER>"TR,#(T,#@Q-"YH=&U02P$"% ,4    " #L.0Y9D2>N(V((
M   U70  $0              @ '>$P  =FER>"TR,#(T,#@Q-"YX<V102P$"
M% ,4    " #L.0Y9 OQDQ!\D  "82P( #P              @ %O'   =FER
M>"UE>#DY7S$N:'1M4$L! A0#%     @ [#D.66*.=6\K&@  _M4   \
M         ( !NT   '9I<G@M97@Y.5\R+FAT;5!+!08     !  $ /@    3
%6P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>virx-20240814_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="virx-20240814.xsd" xlink:type="simple"/>
    <context id="C_98aacdd6-9459-49cf-a10d-38541647a2a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001061027</identifier>
        </entity>
        <period>
            <startDate>2024-08-14</startDate>
            <endDate>2024-08-14</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4"
      id="F_ca979c45-5858-4a02-9874-884e318e77be">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4"
      id="F_0a028806-123e-4bdc-935b-ea0a148292b7">0001061027</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4"
      id="F_c2885d22-9ee6-4caf-a7f2-5e14c607123d">Viracta Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:DocumentType
      contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4"
      id="F_e125bc83-1c41-40c3-9ba6-526038384d6a">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4"
      id="F_1e692be0-a6da-4699-84af-db6d695e8e1c">2024-08-14</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4"
      id="F_6dcfec6a-185a-4f22-bbc4-36b422aaef4e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4"
      id="F_9819ca33-e381-4ee9-98e8-1a75e1e11ba2">000-51531</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4"
      id="F_43878f90-ce9b-449f-91c6-72cfc62041c6">94-3295878</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4"
      id="F_bd5fb67e-7e64-4dae-ad62-21c308b1c814">2533 S. Coast Hwy. 101, Suite 210</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4"
      id="F_09f4e20f-398a-4ca7-b018-9ae74e853f66">Cardiff</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4"
      id="F_a72a948b-bfb1-4f01-80e9-d7fb833560e9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4"
      id="F_88a9ec8c-5c92-4187-be48-e27a9ce5d144">92007</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4"
      id="F_f19b5477-8a2c-42af-b77b-9a410f332c16">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4"
      id="F_05cd1bb2-892b-4704-b6c9-018863a6558d">400-8470</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4"
      id="F_59df26a0-2a43-4b30-8955-9a2a4ed9d042">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4"
      id="F_d5e49025-4db3-4653-894d-8b06e2686966">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4"
      id="F_de06bce0-0a9c-403e-b4ef-d75e8572872e">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4"
      id="F_3ccde49d-f354-4d62-af87-65c8dcbbfa45">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4"
      id="F_11cb11e5-7f01-4f3f-b63f-4a265eb0aab5">Common Stock,  par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4"
      id="F_ab428b9d-902a-49ce-aa3d-583920380000">VIRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4"
      id="F_af1df8bf-ae65-4b89-ae7e-1493dbf9b63e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_98aacdd6-9459-49cf-a10d-38541647a2a4"
      id="F_80af43e0-4b9c-44b1-9585-a4b01fcc81ab">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
